Anisodamine (654-II) 10mg vs Buscopan for Acute Gastric/Intestinal Spasm Pain
Intestinal Diseases
Enrolment: 299 · Results not recorded
Loading the evidence…
Drug · ChEMBL holds NO mechanism record for anisodamine (get_mechanism returned zero rows), so no molecular target is asserted for the anisodamine component. The neostigmine component resolves separately to CHEMBL278020 NEOSTIGMINE (max_phase 4, first approval 2013, ATC N07AA01/N07AA51/S01EB06), an acetylcholinesterase INHIBITOR, target CHEMBL220 (ChEMBL mec_id 737). PARTIAL identity covering the two components individually, NOT the 500:1 fixed combination.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Intestinal Diseases
Enrolment: 299 · Results not recorded
Septic Shock
Enrolment: 355 · Results not recorded
Sepsis
Enrolment: 782 · Results not recorded
Septic Shock · Sepsis · Critical Illness
Enrolment: 20 · Results not recorded
Postoperative Nausea and Vomiting
Enrolment: 90 · Results not recorded
Postoperative Nausea and Vomiting
Enrolment: 300 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute lethal crush syndrome by hind-limb compression under anaesthesia: rats 20 kg block for 5 h, mice 20 kg block for 4 h, rabbits 40 kg block for 6 h, followed by decompression
The combination raised 24 h survival from 13.3 per cent to 86.7 per cent in rats (20 mg/kg plus 40 microgram/kg given 30 min before decompression), from 37.5 per cent to 87.5 per cent in rabbits, and from 30.8 per cent to 69.2 per cent in wild-type mice. It improved mean arterial and systolic blood…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.